6 Recommendations for further research

6 Recommendations for further research

6.1 Further research is recommended on the use of repeat PlGF‑based testing (Triage PlGF test and Elecsys immunoassay sFlt‑1/PlGF ratio), with standard clinical assessment, in women presenting with suspected pre‑eclampsia between 20 weeks and 34 weeks plus 6 days of gestation, who have had a negative PlGF‑based test result (Triage PlGF test result of 100 picograms/ml or more; Elecsys immunoassay sFlt 1/PlGF ratio of less than 38) that was used to rule‑out pre‑eclampsia (see section 5.15). This should include:

  • exploration of the different scenarios in which repeat testing may be indicated

  • the appropriate intervals between PlGF‑based tests

  • the diagnostic accuracy of PlGF‑based testing in women with suspected pre‑eclampsia who have previously had 1 or more negative PlGF‑based test results.

6.2 Further research is recommended on the use of the Triage PlGF test and Elecsys immunoassay sFlt‑1/PlGF ratio, with standard clinical assessment, to rule‑in pre‑eclampsia in women presenting with suspected pre‑eclampsia between 20 weeks and 34 weeks plus 6 days of gestation (see section 5.9). This should specifically investigate how a positive PlGF‑based test result (Triage PlGF test result of 12 picograms/ml or less; Elecsys immunoassay sFlt 1/PlGF ratio of greater than 38) used to rule‑in pre‑eclampsia would affect management decisions on time to delivery and the outcomes associated with this.

  • National Institute for Health and Care Excellence (NICE)